Hedera Dx enables health systems, patients and drug development programs to adopt advanced molecular testing and real-world evidence capabilities. We build in-house NGS and liquid biopsy solutions that bring rapid, hospital laboratory–integrated tumor profiling to clinical care, expanding access to precision therapies.

We provide a full suite of NGS assays (FFPE, ctDNA and RNA) and streamlined software workflows so hospital molecular pathology laboratories can perform liquid and tissue profiling locally. Our solution covers sequencing, clinical reporting and therapy-matching, and supports real-world evidence generation through partnerships and clinical validation studies.

Founded in 2021 and led by experienced diagnostics and oncology leaders, Hedera Dx aims to simplify cancer testing at scale, reduce barriers to advanced testing, and improve treatment outcomes worldwide.